

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of the claims in the application:

### Listing of the Claims


1. (previously presented) A method for assessing the risk of transplantation rejection in a recipient host comprising the following steps:
  - (a) determining the HLA-DR of the recipient and the HLA-DR of a donor and determining if the recipient and donor are DR mismatched;
  - (b) assaying for the presence of activated T-lymphocytes in the recipient;
  - (c) assaying for the presence of circulating IgG anti-HLA Class II antibodies in the serum of the recipient;wherein the presence of activated T-lymphocytes in the recipient and the presence of circulating IgG anti-HLA Class II antibodies in a DR mismatched recipient indicates a high risk of transplantation rejection.
2. (original) The method of claim 1 wherein the recipient host has received a tissue allograft.
3. (original) The method of claim 1 wherein the recipient host has received a heart transplant.
4. (original) The method of claim 1 wherein the HLA-DR of the recipient is determined using a microcytotoxicity assay.
5. (original) The method of claim 1 wherein the HLA-DR of the recipient is determined using a mixed lymphocyte reaction.
6. (original) The method of claim 1 wherein the HLA-DR of the recipient is determined using a polymerase chain reaction.
7. (original) The method of claim 1 wherein the presence of antigen activated lymphocytes is measured using a lymphocyte growth assay.

Claims 8-18 (cancelled).

19. (currently amended) A method for predicting whether or not a ~~post-transplant recipient~~ subject who has received a tissue allograft is likely to reject ~~the~~ a tissue allograft comprising ~~detection of~~ detecting IgG anti-HLA DR antibodies in serum from the subject by determining reactivity of the serum with panels of separated B- and T- lymphocytes from control individuals representative of the most frequently encountered HLA class I and class II antigens and obtaining a ratio of reactivity with B-versus T-lymphocytes, in the serum of the post-transplant recipient against a panel of control B-lymphocytes wherein detection of greater reactivity with B-lymphocytes relative to reactivity with T-lymphocytes indicates that such antibodies are present and indicates that the post-transplant tissue allograft recipient is likely to reject the ~~a~~ tissue allograft.

Entry of the amendments and remarks as stated herein and in the Amendment submitted November 12, 2004, which is incorporated by reference herein in its entirety, into the record is respectfully requested. Claims 1-7 have been allowed, and withdrawal of all rejections and reconsideration of the amended claim 19 is requested.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Lisa B. Kole', is written over a horizontal line.

Lisa B. Kole  
Patent Office Reg. No. 35,225

*Attorney for Applicants*

BAKER BOTTS L.L.P.  
30 Rockefeller Plaza  
New York NY 10112-4498  
(212) 408-2628